

# (12) International Application Status Report

**Received at International Bureau:** 22 May 2020 (22.05.2020)

**Information valid as of:** 20 November 2020 (20.11.2020)

**Report generated on:** 28 February 2021 (28.02.2021)

**(10) Publication number:**

WO2020/231713

**(43) Publication date:**

19 November 2020 (19.11.2020)

**(26) Publication language:**

English (EN)

**(21) Application Number:**

PCT/US2020/031747

**(22) Filing Date:**

07 May 2020 (07.05.2020)

**(25) Filing language:**

English (EN)

**(31) Priority number(s):**

62/846,780 (US)

**(31) Priority date(s):**

13 May 2019 (13.05.2019)

**(31) Priority status:**

Priority document received (in compliance with PCT Rule 17.1)

**(51) International Patent Classification:**

**C07D 409/06** (2006.01); **A61P 35/00** (2006.01)

**(71) Applicant(s):**

BRISTOL-MYERS SQUIBB COMPANY [US/US]; Route 206 and Province Line Road Princeton, New Jersey 08543 (US) *(for all designated states)*

**(72) Inventor(s):**

HARIKRISHNAN, Lalgudi S.; c/o Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, New Jersey 08543 (US)

KAMAU, Muthoni G.; c/o Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, New Jersey 08543 (US)

FINK, Brian E.; c/o Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, New Jersey 08543 (US)

**(74) Agent(s):**

KORSEN, Elliott; Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, New Jersey 08543 (US)

**(54) Title (EN):** AGONISTS OF ROR GAMMA $\alpha$

**(54) Title (FR):** AGONISTS DE ROR-GAMMAT

**(57) Abstract:**

**(EN):** The present invention is directed to compounds of the formula [INSERT CHEMICAL STRUCTURE HERE}] wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

**(FR):** La présente invention concerne des composés de formule [INSERER LA STRUCTURE CHIMIQUE ICI], Tous les substituants étant définis dans la description, ainsi que des compositions pharmaceutiquement acceptables comprenant des composés de l'invention et des procédés d'utilisation desdites compositions dans le traitement de divers troubles.

**International search report:**

Received at International Bureau: 09 July 2020 (09.07.2020) [EP]

**International Report on Patentability (IPRP) Chapter II of the PCT:**

Not available

**(81) Designated States:**

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM

**Declarations:**

Declaration made as applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate

Declaration made as applicant's entitlement, as at the international filing date, to claim the priority of the earlier application, where the applicant is not the applicant who filed the earlier application or where the applicant's name has changed since the filing of the earlier application (Rules 4.17(iii) and 51bis.1(a)(iii))